DNA: AI Drug Deal With Hugging Face, and What Else Investors Should Know

Court: N.D. California

Case: 4:21-cv-08943

Ginkgo Bioworks stock climbs on new collaboration for AI-driven drug discovery

• Ginkgo Bioworks DNA jumped nearly 4% after announcing a partnership with Hugging Face to release high-quality biological datasets designed for machine learning applications.
• The goal is to accelerate drug development by making biological data more accessible to AI researchers. The first release, the GDPx and GDPa datasets, was described as offering a “x1000 boost to AI for drug development,” according to Hugging Face’s team.
• The deal highlights growing investor interest in the intersection of synthetic biology and AI — a space Ginkgo has been actively expanding through partnerships.

Other concerns about DNA that any investor might want to know

• At the same time, Ginkgo Bioworks agreed to a $17.75 million settlement with investors over claims stemming from the Scorpion Capital report and alleged reliance on related parties for revenue.
• You can check more information about it and file for a payout here.